Versartis Inc (VSAR)

12.98
0.38 3.00
NASDAQ : Health Care
Prev Close 12.60
Open 12.58
Day Low/High 12.52 / 13.47
52 Wk Low/High 6.17 / 14.54
Volume 14.98K
Avg Volume 110.50K
Exchange NASDAQ
Shares Outstanding 29.54M
Market Cap 389.35M
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Versartis Reports Second Quarter 2016 Financial Results

Versartis Reports Second Quarter 2016 Financial Results

Enrollment to be Complete by Mid-August in the Phase 3 VELOCITY Trial for Pediatric GHD; Data Expected Q3 2017

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

8 Biotech Stocks Under $10 Making Big Moves Higher

8 Biotech Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

RSI Alert: Versartis (VSAR) Now Oversold

RSI Alert: Versartis (VSAR) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

VSAR: Insiders vs. Shorts

VSAR: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 01/29/2016 settlement date, and Versartis Inc is one of the most shorted stocks of the Russell 3000, based on 5.85 "days to cover" versus the median component at 4.92. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Versartis' VRS-317 6-Month Data Published In The Journal Of Clinical Endocrinology & Metabolism

Versartis' VRS-317 6-Month Data Published In The Journal Of Clinical Endocrinology & Metabolism

Results Show Positive Safety and Efficacy Data With Similar Outcomes Across Three Dosing Regimens

VSAR: Insiders vs. Shorts

VSAR: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 10/30/2015 settlement date, and Versartis Inc is one of the most shorted stocks of the Russell 3000, based on 11.77 "days to cover" versus the median component at 5.62. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ESPE Annual Meeting

Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ESPE Annual Meeting

Data From Ongoing Pediatric Extension Study Confirms Dose Used in VELOCITY Phase 3 Trial Provides Stable Second Year Growth Rates and Similar Safety Profile to Daily Treatment

Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study Of Somavaratan In GHD Children

Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study Of Somavaratan In GHD Children

Late-Breaking Data Show 3.5 mg/kg Twice-Monthly Dosing Increased Mean Peak IGF-I SDS and Stabilized 12 to 18 Month Mean Height Velocity While Maintaining Safety Profile

Versartis To Host Investor Symposium Featuring Global Opinion Leaders In Pediatric Human Growth Hormone Deficiency

Versartis To Host Investor Symposium Featuring Global Opinion Leaders In Pediatric Human Growth Hormone Deficiency

International Panel of Pediatric Endocrinologists to Provide Perspectives on GHD